• Market Capitalisation market-capitalisation-info $58 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-103 Mln

Tcr2 Therapeutics Inc (TCRR) Share Price

$1.48

As on 01-Jun-2023 09:30 EST

$0.000.00%

  • Prev Close info

    $1.48

  • Day's Openinfo

    $1.48

  • Today's Highinfo

    $1.48

  • Today's Lowinfo

    $1.48

  • Today's Volumeinfo

    --

  • 52 Week rangeinfo

    $0.82 - 3.88

Please wait...

Tcr2 Therapeutics Inc (TCRR) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Tcr2 Therapeutics Inc (TCRR)
48.15 -16.15 18.40 -36.21 -47.28 -- --
S&P BSE Sensex*
14.94 7.74 5.00 12.46 15.02 14.87 12.65
#
-- -- -- -- -- -- --
As on 01-Jun-2023  |  *As on 11-Dec-2023  |  #As on
2022
2021
2020
Tcr2 Therapeutics Inc (TCRR)
-78.56 -84.93 116.60
S&P BSE Sensex
4.44 21.99 15.75
S&P BSE Sensex
4.44 21.99 15.75

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Tcr2 Therapeutics Inc (TCRR) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Tcr2 Therapeutics Inc (TCRR)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Tcr2 Therapeutics Inc (TCRR)

        Pres, CEO & Director

        Dr. Garry E. Menzel M.B.A., Ph.D.

        Founder & Member of the Advisory Board

        Dr. Patrick A. Baeuerle Ph.D.

        Headquarters

        Cambridge, MA

        FAQs for Tcr2 Therapeutics Inc (TCRR)

        The total asset value of Tcr2 Therapeutics Inc (TCRR) stood at $ 199 Mln as on 31-Mar-23

        The share price of Tcr2 Therapeutics Inc (TCRR) is $1.48 (NASDAQ) as of 01-Jun-2023 09:30 EST. Tcr2 Therapeutics Inc (TCRR) has given a return of -47.28% in the last 3 years.

        Tcr2 Therapeutics Inc (TCRR) has a market capitalisation of $ 58 Mln as on 01-Jun-2023. As per Value Research classification, it is a company.

        The P/B ratio of Tcr2 Therapeutics Inc (TCRR) is 0.22 times as on 01-Jun-2023, a -0.91% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Tcr2 Therapeutics Inc (TCRR) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Tcr2 Therapeutics Inc (TCRR) and enter the required number of quantities and click on buy to purchase the shares of Tcr2 Therapeutics Inc (TCRR).

        TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

        The CEO & director of Dr. Garry E. Menzel M.B.A., Ph.D.. is Tcr2 Therapeutics Inc (TCRR), and CFO & Sr. VP is Dr. Patrick A. Baeuerle Ph.D..

        The promoters of Tcr2 Therapeutics Inc (TCRR) have pledged 0% of the total equity as on Mar-23.

        Tcr2 Therapeutics Inc (TCRR) Ratios
        Return on equity(%)
        -111.47
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Tcr2 Therapeutics Inc (TCRR) was $-103 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $58.11 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-102.59 Mln
        • Cash date-information $110.31 Mln
        • Total Debt info $5.98 Mln
        • Insider's Holding 1.50%
        • Liquidity liquidity
        • 52 Week range week-range $0.82 - 3.88
        • Shares outstanding share-outstanding 39,261,700
        • 7 Years Aggregate:

          CFO: $-321.36 Mln

          EBITDA: $-350.46 Mln

          Net Profit: $-413.59 Mln

        About The Company

        • IPO Date 14-Feb-2019
        • Pres, CEO & Director Dr. Garry E. Menzel M.B.A., Ph.D.
        • Founder & Member of the Advisory Board Dr. Patrick A. Baeuerle Ph.D.
        • Listing key-listing NASDAQ: TCRR
        • Country United States
        • Headquarters headquarters Cambridge, MA
        • Website website https://www.tcr2.com
        • Business

          TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells)...  targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon